Y-Intercept (HK)’s Fate Therapeutics FATE Stock Holding History

Y-Intercept (HK)’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$121K	Buy	+44,773	New	+$82.9K	﹤0.01%	1600
2025 Q1	–	Sell	-35,360	Closed	-$58.3K	–	1322
2024 Q4	$58.3K	Buy	+35,360	New	+$89.1K	﹤0.01%	1116
2024 Q3	–	Sell	-17,053	Closed	-$55.9K	–	1472
2024 Q2	$55.9K	Buy	+17,053	New	+$74.7K	﹤0.01%	1296
2023 Q4	–	Sell	-95,698	Closed	-$203K	–	1360
2023 Q3	$203K	Buy	95,698 +63,116	+194%	+$209K	0.02%	910
2023 Q2	$155K	Buy	+32,582	New	+$180K	0.02%	978
2021 Q4	–	Sell	-6,376	Closed	-$378K	–	670
2021 Q3	$378K	Buy	6,376 +1,248	+24%	+$97.9K	0.07%	410
2021 Q2	$445K	Buy	+5,128	New	+$413K	0.11%	293

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Y-Intercept (HK)'s FATE Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in Fate Therapeutics (FATE) in Q2 2026: 44,773 shares worth $121K. The stake represents ﹤0.01% of the portfolio and ranks #1600 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in FATE as recently as Q4 2024.

Y-Intercept (HK) first reported a position in FATE in Q2 2021 and has held it in 7 quarters since. The position peaked at $445K in Q2 2021. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

Y-Intercept (HK) held 44,773 shares of Fate Therapeutics worth $121K as of Q2 2026.
Fate Therapeutics was a new Y-Intercept (HK) position in Q2 2026.
Fate Therapeutics made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1600 holding.
Y-Intercept (HK) first reported a position in Fate Therapeutics in Q2 2021 and has held it in 7 quarters since.
Y-Intercept (HK)'s Fate Therapeutics position peaked at $445K in Q2 2021.
156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.